Invests in
Sectors:
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- TU
Lists including Hiromichi
Investments
Work Experience
2024
Entrepreneur, Founder, Global Life Science Investor, Professorship (2018-)
2024
Entrepreneur, Founder (Stealth startup in preparation), Global Life Science Investor, Professorship(2018-present), Advisor for several global consulting firms
2023 - 2024
Director/Lead
2023 - 2024
Business Development, Corporate Development, Strategic Operation Global Search and Evaluation, support for Early stage Bioventure VC collaboration strategy Commercial product marketing strategy planning and development
2018 - 2023
Investment Director
2018 - 2023
Strategic Biotech Investor, Board Director (Casma, DEM Bio, NeoPhore, Solu, Others), NewCo creation, Advisory member (Top tier venture funds), Academic appointment (The University of Tokyo) Led and achieved 11 qualified investments to early stage Bioventures and built 3 strategic LP partnerships with top 1&2 venture capitals from deal due diligence to execution of agreements under my supervision last 2 years. Some of Bioventures have reached out to Pharma deals. The activity has been ranked at 7th global Pharma CVC, reported in Silicon Valley Bank Report 2021 Organization management to upgrade to professional global standard including budget, people, legal, IP, venture capital tasks.
2014 - 2018
Research Manager/Senior Director
2014 - 2018
Post merger integration as cross-functional leadership in Research and Manufacture, IP & legal (Ganymed<VYROY>, Ogeda<VEOZA>, Quethera), Oncology drug discovery, Management of Local and Global research collaborations including CRUK, Translational Science, Project based partnership Management: People, Budget, Legal documents, External relationships Supervised/managed over 10 oncology programs Co-founded Kyoto University-Astellas Drug discovery incubator in Kyoto University.
2013 - 2014
Dual position/Associate Director/Research head/Head of Department in Pharmacology
2013 - 2014
Protein homeostasis in Oncology
2007 - 2014
Associate Director/Research head/Head of Department in Pharmacology (SRC)
2007 - 2014
Drug discovery (generated first in class 10+ programs as lead and Head), Translational Science in Oncology, Global organizational collaboration with Takeda San Francisco, Takeda San Diego, and Millennium: Takeda Oncology Management: People, Budget, Organization, Annual planning, cross-functional projects
2001 - 2007
Postdoctoral Research Associate (Tom Curran, FRS lab)
2001 - 2007
Academic independent position (2006-2007) Basic and Translational Science in Oncology Long-term collaboration with Genentech (Fred de Sauvage) and Curis (Lee Rubin) for Drug Discovery and Translational Science in Hedgehog Antagonist Program (Vismodegib has been Approved by FDA in 2012, now became blockbaster) AACR Scholar in Awards (2003, 2006, 2007) International Congress Biochemistry and Molecular Biology Young Scientist Award (2006) International Congress Biochemistry and Molecular Biology Best Presentation Award (2006)
2000 - 2002
Postdoctoral Research Fellow of JSPS for Young Scientist
2000 - 2002
Molecular biology, Cellular proliferation, Epigenetics
1993 - 1994
Clinical Development Associate
1993 - 1994
Early-career role in clinical development, working within a planning team for drug development strategy of Finibax Ph2 study. This foundational experience helped shape a cross-functional perspective on R&D, medical, and regulatory dynamics.